Literature DB >> 1866137

Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid.

R Neumann1, J Tauber, C S Foster.   

Abstract

Ocular cicatricial pemphigoid (OCP) is a chronic, progressive, autoimmune disease that scars mucus membranes and may lead to blindness. The authors studied the long-term effects of OCP in 104 consecutive patients (average follow-up, 4 years) to determine whether complete remission could be achieved after a course of treatment with immunosuppressive drugs. Prolonged periods of remission while not undergoing therapy were maintained in approximately one third of patients with OCP. Follow-up must be continued for life, as relapse occurred in 22% of those who were in remission and not undergoing therapy. Those who relapsed regained disease control readily upon reinstitution of therapy and did not deteriorate to more advanced cicatrization. Sex, age, initial degree of inflammation, and the incidence of extraocular involvement did not have a prognostic significance on outcome. Mechanisms that underlie the differing responses to therapy are not yet known.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1866137     DOI: 10.1016/s0161-6420(91)32209-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  9 in total

1.  [Mycophenolate mofetil as effective therapy option in scarring pemphigoid].

Authors:  I Elser; D Selimovic; T Ruzicka; A Kuhn; M Megahed
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

Review 2.  Autoimmune bullous diseases: ocular manifestations and management.

Authors:  Caroline Laforest; Shyamala C Huilgol; Robert Casson; Dinesh Selva; Igal Leibovitch
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Intravenous immunoglobulin in eye involvement.

Authors:  Zera Tellier
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

4.  Combination treatment of intravenous immunoglobulin and cultivated oral mucosal epithelial transplantation for ocular cicatricial pemphigoid.

Authors:  Y Uchino; S Takahashi; M Uchino; J Shimazaki
Journal:  Br J Ophthalmol       Date:  2007-01       Impact factor: 4.638

5.  Combination treatment of intravenous immunoglobulin and cultivated oral mucosal epithelial transplantation for ocular cicatricial pemphigoid.

Authors:  Y Uchino; M Uchino; J Shimazaki
Journal:  BMJ Case Rep       Date:  2009-02-02

Review 6.  The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.

Authors:  J K Dart
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

Review 7.  [Mucous membrane pemphigoid with ocular involvement. Part II: therapy].

Authors:  T Meyer-ter-Vehn; E Schmidt; D Zillikens; G Geerling
Journal:  Ophthalmologe       Date:  2008-04       Impact factor: 1.059

8.  Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study.

Authors:  Caiyun You; Neerav Lamba; Andres F Lasave; Lina Ma; Mikhail Hernandez Diaz; C Stephen Foster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-03       Impact factor: 3.535

9.  Treatment strategies in mucous membrane pemphigoid.

Authors:  Ann G Neff; Matthew Turner; Diya F Mutasim
Journal:  Ther Clin Risk Manag       Date:  2008-06       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.